全球生物制药巨头艾伯维公司近日透露，已启动与美国多个州的实质性谈判，旨在扩大其本土制造产能布局。据悉，此次战略磋商涉及新型生产设施建设及现有基地升级，预计在2026年将公布新一轮具体投资方案。
此次跨州谈判凸显了艾伯维强化供应链韧性的长期战略。通过分散化产能布局，企业既能应对地缘政治风险，又可依托各州差异化产业政策优化运营效率。值得注意的是，2026年的投资窗口期恰逢多项专利到期关键节点，此举或为下一代明星产品的商业化提前铺路。
行业观察人士指出，生物制药企业的属地投资决策往往伴随税收优惠、人才引进等配套政策。艾伯维此番多线推进，既反映了其对美国本土创新生态的持续押注，也暗合拜登政府《通胀削减法案》对医药制造业的回流激励。随着谈判深入，具体投资规模与就业创造效应将成为各州争抢项目的关键变量。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.